Skip to main content

ixekizumab

Generic: ixekizumab·Brand: Taltz

ixekizumab: developed by 1 company · 4 clinical trials tracked · 1 FDA decision.

ixekizumab evidence translation

What we can confirm

1 FDA record · 4 tracked trials

What it means

Source-backed records connect ixekizumab to LLY; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could ixekizumab → LLY affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence5 indications · 0 study sponsors

Related indications

For the treatment of adults and pediatric patients aged 6 years or older with moderate to severe plaque psoriasis; adults with active psoriatic arthritis; adults with ankylosing spondylitis; and adults with active non-radiographic axial spondyloarthritis.Psoriatic Arthritis; Juvenile Psoriatic Arthritis; PsoriasisObesityPsoriasisPsoriatic Arthritis

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (2)
CompanyPhase
ELI LILLY & Co (LLY)
For the treatment of adults and pediatric patients aged 6 ye…
Approved
ELI LILLY & Co (LLY)
Psoriatic Arthritis; Juvenile Psoriatic Arthritis; Psoriasis
Phase 4
Clinical Trials (4)

Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis

NCT07443956·N/A
Recruiting

Primary endpoint: Correlation of molecular changes in biopsies (skin, synovial and adipose) with weight loss

InterventionalRandomizedopen45 targetStarted 2026-03Completion 2030-054 sites · United KingdomNHS Greater Glasgow and Clyde

Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO)

NCT06588283·Phase 3·LLY
Completed

Primary endpoint: Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight Reduction

InterventionalRandomizedopen281 enrolledStarted 2024-09Completion 2026-0650 sites · United StatesEli Lilly and Company

Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsA)

NCT06588296·Phase 3·LLY
Completed

Primary endpoint: Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction

InterventionalRandomizedopen279 enrolledStarted 2024-09Completion 2026-0450 sites · United StatesEli Lilly and Company

Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

NCT04527380·Phase 3·LLY
Active, not recruiting

Primary endpoint: Percentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 (Ixekizumab - OLT Period)

InterventionalRandomizedopen101 enrolledStarted 2021-04Completion 2029-0143 sites · Argentina, Belgium, Czechia, Denmark…Eli Lilly and Company
FDA Decisions1 records
Approval(LLY)FDA ↗
BLA125521Type 1 - New Molecular EntityStandardOtherInjectable

Frequently asked questions

Who is developing ixekizumab?

ixekizumab is being developed by ELI LILLY & Co.

How many clinical trials involve ixekizumab?

BioSniper tracks 4 clinical trials involving ixekizumab.

What is ixekizumab's latest FDA decision?

The most recent tracked FDA decision for ixekizumab is Approval, dated March 22, 2016.